Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer

Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer

Abstract Background TAS-102 plus bevacizumab is an anticipated combination regimen for patients who have metastatic colorectal cancer. However, evidence supporting its use for this indication is limited. We compared the cost-effectiveness of TAS-102 plus bevacizumab combination therapy with TAS-102...

Full description

Bibliographic Details
Main Authors: Kiyoaki Sugiura, Yuki Seo, Takayuki Takahashi, Hideyuki Tokura, Yasuhiro Ito, Motomu Tanaka, Norihiro Kishida, Yusuke Nishi, Yoshihiko Onishi, Hikaru Aoki
Format: Article
Language:English
Published: BMC 2021-04-01
Series:BMC Gastroenterology
Subjects:
Colorectal cancer
TAS-102
Bevacizumab
Cost-effectiveness
Online Access:https://doi.org/10.1186/s12876-021-01771-z

Internet

https://doi.org/10.1186/s12876-021-01771-z

Similar Items